Spain Advances in Regulating Medicinal Cannabis Amidst Calls for Broader Accessibility

In a pivotal move, Spain’s Ministry of Health has initiated the process of regulating medicinal cannabis, signaling a significant policy shift towards accommodating therapeutic use of the plant. The draft Royal Decree, now open for public consultation, aims to establish comprehensive guidelines for the utilization of cannabis in medical treatment, with an emphasis on diseases where the risk-benefit ratio is demonstrably favorable. This development is particularly pertinent for patients suffering from severe and debilitating conditions, including cancer, who have long advocated for legal access to cannabis-based therapies.

As the legislative framework takes shape, the Ministry underscores its commitment to grounding the regulation in the “best scientific evidence available,” ensuring that the application of medicinal cannabis is both safe and effective. This approach reflects a growing recognition of cannabis’s potential benefits in managing symptoms and improving the quality of life for individuals with chronic illnesses.

The push for regulation gained momentum thanks to the advocacy of figures such as Carola Pérez, President of the Dosemociones Association and the Spanish Observatory for Medicinal Cannabis. Pérez, a vocal proponent for medicinal cannabis, has highlighted the delays in regulatory action and called for a more accessible framework for patients. “We are more than a year behind schedule since the approval by the Health Commission for the use of medicinal cannabis,” Pérez stated in a Radio 5 interview with Daniel Gamboa, expressing gratitude towards Mónica García and Javier Padilla for their roles in advancing this cause.

Pérez has also criticized the proposed model for dispensing medicinal cannabis exclusively through hospital pharmacies, pointing out the logistical challenges and potential for exacerbating hospital congestion. She emphasizes the need for patients to have precise control over the dosage of active substances to reap therapeutic benefits without undesirable psychoactive effects. According to Pérez, regulatory oversight is crucial in addressing these concerns and ensuring that patients have reliable access to quality-controlled medicinal cannabis.

The inclusion of cancer patients in the regulation marks a significant expansion of the eligible conditions for cannabis-based treatments, moving beyond the previously limited scope that covered epilepsy, spasticity, and multiple sclerosis. The Health Ministry’s proactive stance, spearheaded by Minister Mónica García, aims to expedite the legislative process and broaden the range of conditions that qualify for cannabis therapy. This includes not only cancer but also multiple sclerosis, certain forms of epilepsy, and symptoms related to chemotherapy, among others.

As Spain progresses towards formalizing medicinal cannabis use, the ongoing public consultation offers an opportunity for stakeholders to shape the future of cannabis regulation. The initiative reflects a broader shift towards evidence-based, patient-centered approaches in healthcare policy, acknowledging the therapeutic potential of cannabis while addressing the need for stringent regulatory oversight to ensure patient safety and access.

The timing of these regulatory advancements could not be more opportune, as announces an exclusive partnership with the International Cannabis Business Conference (ICBC) and Spannabis in Barcelona. This collaboration is set to significantly enhance networking opportunities and foster the development of the medicinal cannabis market in Spain. The ICBC x Spannabis event, renowned for bringing together industry leaders, investors, and innovators, will serve as a pivotal platform for stakeholders to explore the burgeoning medical cannabis landscape in Spain.

Scroll to Top